Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the AntiClastic ASO platform, to chair Alloy’s genetic medicines scientific advisory board (SAB). BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Cell therapy utilizing chimeric antigen receptors (CARs) for immunotherapy of cancer show great promise as treatments of blood cancers. CARs are composed of an antigen binding domain linked to a signaling domain, which collectively enables recognition of the cancer antigen and activation of the CAR-T cells. Therapeutically active CARs require high levels of antigen binding […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Last year Moderna’s former head of infectious disease described vaccine lipid nanoparticle (LNP) delivery technology “unsung hero of the whole thing.” The whole thing being the mRNA COVID-19 vaccine administered to hundreds of millions around the globe, through both Pfizer and Moderna. Proper delivery that protected the fragile messenger RNA molecular was critical in making […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Our mission has always been to democratize biologics discovery technology and capabilities so that the widest possible audience of scientists can access them to develop promising therapeutics for patients. We both create platforms and build discovery services groups that are expert in using and improving these platforms for the benefit of all. We are excited […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Partnering with Target-Rich Biotech Companies
Running a successful early-stage biotech company requires a careful balance of enterprise and discipline. Companies must develop disruptive new discovery technologies or insights into disease biology that can have broad applications, but they must choose their first disease application(s) carefully. This tension is in large part driven by the demands around financing a startup biotech […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]